The stock has a 36-month beta value of 1.10. Opinions on the stock are mixed, with 10 analysts rating it as a “buy,” 6 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for BBIO is 160.74M, and at present, short sellers hold a 13.93% of that float. On June 04, 2025, the average trading volume of BBIO was 2.96M shares.
BBIO) stock’s latest price update
BridgeBio Pharma Inc (NASDAQ: BBIO) has seen a rise in its stock price by 5.81 in relation to its previous close of 35.46. However, the company has experienced a 13.35% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-02 that PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami, FL on Monday, June 9 at 8:40 am ET.
BBIO’s Market Performance
BBIO’s stock has risen by 13.35% in the past week, with a monthly drop of -2.72% and a quarterly rise of 11.87%. The volatility ratio for the week is 1.31% while the volatility levels for the last 30 days are 3.08% for BridgeBio Pharma Inc The simple moving average for the past 20 days is 9.63% for BBIO’s stock, with a 24.20% simple moving average for the past 200 days.
Analysts’ Opinion of BBIO
Many brokerage firms have already submitted their reports for BBIO stocks, with Redburn Atlantic repeating the rating for BBIO by listing it as a “Buy.” The predicted price for BBIO in the upcoming period, according to Redburn Atlantic is $50 based on the research report published on March 31, 2025 of the current year 2025.
BBIO Trading at 8.35% from the 50-Day Moving Average
After a stumble in the market that brought BBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.11% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BBIO starting from Kumar Neil, who sale 75,000 shares at the price of $33.40 back on May 20 ’25. After this action, Kumar Neil now owns 4,798,447 shares of BridgeBio Pharma Inc, valued at $2,504,978 using the latest closing price.
Kumar Neil, the Chief Executive Officer of BridgeBio Pharma Inc, sale 26,156 shares at $33.33 during a trade that took place back on May 19 ’25, which means that Kumar Neil is holding 217,404 shares at $871,764 based on the most recent closing price.
Stock Fundamentals for BBIO
Current profitability levels for the company are sitting at:
- -5.48 for the present operating margin
- 0.97 for the gross margin
The net margin for BridgeBio Pharma Inc stands at -5.24. The total capital return value is set at -0.96.
Based on BridgeBio Pharma Inc (BBIO), the company’s capital structure generated -0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -49.43. The debt to equity ratio resting at -0.01. The interest coverage ratio of the stock is -5.91.
Currently, EBITDA for the company is -436.83 million with net debt to EBITDA at 0.96. When we switch over and look at the enterprise to sales, we see a ratio of 51.75. The receivables turnover for the company is 1.11for trailing twelve months and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.57.
Conclusion
To sum up, BridgeBio Pharma Inc (BBIO) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
